Adaptive Biotechnologies Corp
ADPT12.270USD
+0.290+2.42%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.86BCap. mercado
PérdidaP/E TTM
Más Datos de Adaptive Biotechnologies Corp Compañía
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Información de la empresa
Símbolo de cotizaciónADPT
Nombre de la empresaAdaptive Biotechnologies Corp
Fecha de salida a bolsaJun 27, 2019
Fundada en2009
Director ejecutivoMr. Chad M. Robins
Número de empleados619
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 27
Dirección1165 Eastlake Ave E
CiudadSEATTLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal98109
Teléfono12066590067
Sitio Webhttps://www.adaptivebiotech.com
Símbolo de cotizaciónADPT
Fecha de salida a bolsaJun 27, 2019
Fundada en2009
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Director
Independent Director
54.30K
+41.54%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.39K
-3.91%
Ms. Karina Calzadilla
Ms. Karina Calzadilla
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Julie Rubinstein
Ms. Julie Rubinstein
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
MRD revenue
145.53M
81.32%
Immune meidicine revenue
33.43M
18.68%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
MRD revenue
145.53M
81.32%
Immune meidicine revenue
33.43M
18.68%
Estadísticas de accionistas
Actualizado: mié., 11 de jun
Actualizado: mié., 11 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Viking Global Investors LP
19.74%
Rubric Capital Management LP
8.63%
The Vanguard Group, Inc.
7.32%
BlackRock Institutional Trust Company, N.A.
6.45%
Columbia Threadneedle Investments (US)
4.27%
Other
53.59%
Accionistas
Accionistas
Proporción
Viking Global Investors LP
19.74%
Rubric Capital Management LP
8.63%
The Vanguard Group, Inc.
7.32%
BlackRock Institutional Trust Company, N.A.
6.45%
Columbia Threadneedle Investments (US)
4.27%
Other
53.59%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
53.09%
Investment Advisor
23.82%
Hedge Fund
17.68%
Individual Investor
2.66%
Research Firm
2.15%
Private Equity
0.68%
Venture Capital
0.40%
Bank and Trust
0.30%
Pension Fund
0.28%
Participación institucional
Actualizado: sáb., 22 de feb
Actualizado: sáb., 22 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
476
143.19M
94.26%
-9.97M
2024Q4
481
143.31M
96.47%
-18.10M
2024Q3
478
143.38M
97.20%
-27.99M
2024Q2
486
149.83M
101.63%
-16.40M
2024Q1
506
146.67M
99.58%
-10.66M
2023Q4
529
145.23M
100.12%
-16.05M
2023Q3
531
142.64M
98.54%
-11.65M
2023Q2
545
137.84M
95.31%
-15.76M
2023Q1
577
135.96M
94.24%
-11.97M
2022Q4
616
132.93M
92.90%
-17.07M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Viking Global Investors LP
29.99M
20.19%
--
--
Dec 31, 2024
Rubric Capital Management LP
14.60M
9.83%
+200.00K
+1.39%
Dec 31, 2024
The Vanguard Group, Inc.
10.69M
7.19%
+47.48K
+0.45%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
9.81M
6.6%
+55.67K
+0.57%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
6.83M
4.6%
-900.75K
-11.65%
Dec 31, 2024
ARK Investment Management LLC
9.42M
6.34%
-2.18M
-18.77%
Dec 31, 2024
Millennium Management LLC
6.29M
4.24%
-3.11M
-33.06%
Dec 31, 2024
Aristotle Atlantic Partners, LLC
2.89M
1.94%
-114.50K
-3.82%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
ARK Genomic Revolution ETF
4.33%
ROBO Global Healthcare Technology & Innovation ETF
1.82%
Franklin Genomic Advancements ETF
1.53%
First Trust Small Cap Growth AlphaDEX Fund
0.84%
Invesco NASDAQ Future Gen 200 ETF
0.7%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.49%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
First Trust Small Cap Core Alphadex Fund
0.41%
iShares Micro-Cap ETF
0.2%
Invesco Nasdaq Biotechnology ETF
0.14%
Ver más
ARK Genomic Revolution ETF
Proporción4.33%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.82%
Franklin Genomic Advancements ETF
Proporción1.53%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.84%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.7%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.49%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.49%
First Trust Small Cap Core Alphadex Fund
Proporción0.41%
iShares Micro-Cap ETF
Proporción0.2%
Invesco Nasdaq Biotechnology ETF
Proporción0.14%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
